Research
Hormonal
GLP-1 receptor agonists have demonstrated cardioprotection in patients with type 2 diabetes and heart failure.
Incorporating GLP-1RAs into treatment plans may improve cardiovascular outcomes in diabetic patients.
StrongSupportsmedium confidence
Metformin, sodium-glucose cotransporter 2 inhibitors (SGLT2i) and more recently, glucagon-like peptide-1 receptor agonists (GLP-1RAs), have demonstrated cardioprotection with their administration.
Why this rating
The claim is supported by clinical evidence of drug efficacy.
Source
Advances in incretin therapies for targeting cardiovascular disease in diabetes
Timothy D. Roberts et al. · Journal of Molecular and Cellular Cardiology · 2025
reviewCited 3×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →